Skip to main content

Advertisement

Experimental therapeutics and drug development

This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.

Page 4 of 11

  1. There have been few data on the chemotherapy in elderly advanced non-small cell lung cancer (NSCLC) patients with poor performance status (PS), and usefulness of chemotherapy for such patients remains unclear....

    Authors: Satoshi Ikeda, Hiroshige Yoshioka, Satoshi Ikeo, Mitsunori Morita, Naoyuki Sone, Takashi Niwa, Akihiro Nishiyama, Toshihide Yokoyama, Akimasa Sekine, Takashi Ogura and Tadashi Ishida

    Citation: BMC Cancer 2017 17:797

    Content type: Research article

    Published on:

  2. Quantifying the response of cell lines to drugs or other perturbagens is the cornerstone of pre-clinical drug development and pharmacogenomics as well as a means to study factors that contribute to sensitivity...

    Authors: Nicholas A. Clark, Marc Hafner, Michal Kouril, Elizabeth H. Williams, Jeremy L. Muhlich, Marcin Pilarczyk, Mario Niepel, Peter K. Sorger and Mario Medvedovic

    Citation: BMC Cancer 2017 17:698

    Content type: Software

    Published on:

  3. Neoplastic cells proliferate rapidly and obtain requisite building blocks by reprogramming metabolic pathways that favor growth. Previously, we observed that prostate cancer cells uptake and store lipids in th...

    Authors: Ranjana Mitra, Thuc T. Le, Priyatham Gorjala and Oscar B. Goodman Jr.

    Citation: BMC Cancer 2017 17:631

    Content type: Research article

    Published on:

  4. Programmed cell death 1 (PD1) inhibitors have recently shown promising anti-cancer effects in a number of solid tumor types. A predictive biomarker to this class of drugs has not been clearly identified; howev...

    Authors: Basile Tessier-Cloutier, Steve E. Kalloger, Mohammad Al-Kandari, Katy Milne, Dongxia Gao, Brad H. Nelson, Daniel J. Renouf, Brandon S. Sheffield and David F. Schaeffer

    Citation: BMC Cancer 2017 17:618

    Content type: Research article

    Published on:

  5. Metastatic pancreatic cancer has a dismal prognosis, with a mean six-month progression-free survival of approximately 50% and a median survival of about 11 months. Despite intensive research, only slight impro...

    Authors: Jacek Hajda, Monika Lehmann, Ottheinz Krebs, Meinhard Kieser, Karsten Geletneky, Dirk Jäger, Michael Dahm, Bernard Huber, Tilman Schöning, Oliver Sedlaczek, Albrecht Stenzinger, Niels Halama, Volker Daniel, Barbara Leuchs, Assia Angelova, Jean Rommelaere…

    Citation: BMC Cancer 2017 17:576

    Content type: Study protocol

    Published on:

  6. Mutations of the DNA repair proteins BRCA1/2 are synthetically lethal with the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), which when inhibited, leads to cell death due to the absence of compensatory...

    Authors: Zhor Senhaji Mouhri, Elliot Goodfellow and Bertrand Jean-Claude

    Citation: BMC Cancer 2017 17:540

    Content type: Research article

    Published on:

  7. 177Lu-octreotate can be used to treat somatostatin receptor expressing neuroendocrine tumors. It is highly effective in animal models, but clinical studies have so far only demonstrate...

    Authors: Johan Spetz, Britta Langen, Nils Rudqvist, Toshima Z. Parris, Khalil Helou, Ola Nilsson and Eva Forssell-Aronsson

    Citation: BMC Cancer 2017 17:528

    Content type: Research article

    Published on:

  8. Non-small cell lung cancer is the most common type of lung cancer. Surgery is proven to be the most effective treatment in early stages, despite its potential impact on quality of life. Pulmonary rehabilitatio...

    Authors: Stefania Fugazzaro, Stefania Costi, Carlotta Mainini, Besa Kopliku, Cristian Rapicetta, Roberto Piro, Roberta Bardelli, Patricia Filipa Sobral Rebelo, Carla Galeone, Giorgio Sgarbi, Filippo Lococo, Massimiliano Paci, Tommaso Ricchetti, Silvio Cavuto, Domenico Franco Merlo and Sara Tenconi

    Citation: BMC Cancer 2017 17:508

    Content type: Study protocol

    Published on:

  9. Metformin is a biguanide oral hypoglycaemic agent commonly used for the treatment of type 2 diabetes mellitus. In addition to its anti-diabetic effect, metformin has also been associated with a reduced risk of...

    Authors: Danielle Crawley, Ashish Chandra, Massimo Loda, Cheryl Gillett, Paul Cathcart, Ben Challacombe, Gary Cook, Declan Cahill, Aida Santa Olalla, Fidelma Cahill, Gincy George, Sarah Rudman and Mieke Van Hemelrijck

    Citation: BMC Cancer 2017 17:494

    Content type: Study protocol

    Published on:

  10. Cytotoxic efficacy of anticancer drugs has been widely studied with monolayer-cultured cancer cells. However, the efficacy of drugs under two-dimensional (2D) culture condition usually differs from that of thr...

    Authors: Eva Lhuissier, Céline Bazille, Juliette Aury-Landas, Nicolas Girard, Julien Pontin, Martine Boittin, Karim Boumediene and Catherine Baugé

    Citation: BMC Cancer 2017 17:490

    Content type: Research article

    Published on:

  11. As cancer metastasis is the deadliest aspect of cancer, causing 90% of human deaths, evaluating the molecular mechanisms underlying this process is the major interest to those in the drug development field. Bo...

    Authors: Shih-Hsin Tu, Yi-Chen Hsieh, Li-Chi Huang, Chun-Yu Lin, Kai-Wen Hsu, Wen-Shyang Hsieh, Wei-Ming Chi and Chia-Hwa Lee

    Citation: BMC Cancer 2017 17:440

    Content type: Research article

    Published on:

  12. Studies comparing the effect of antiangiogenic agents targeting different angiogenic pathways are sparse. The purpose of this study was to compare the effect of properdistatin and sunitinib treatment in a prec...

    Authors: Jon-Vidar Gaustad, Trude G. Simonsen, Lise Mari K. Andersen and Einar K. Rofstad

    Citation: BMC Cancer 2017 17:411

    Content type: Research article

    Published on:

  13. Doxorubicin (DXR) hydrochloride (HCl) liposome injection is an important part of the treatment armamentarium for a number of cancers. With growing needs for affordable and effective anticancer treatments, the ...

    Authors: Vinod Burade, Subhas Bhowmick, Kuntal Maiti, Rishit Zalawadia, Harry Ruan and Rajamannar Thennati

    Citation: BMC Cancer 2017 17:405

    Content type: Research article

    Published on:

  14. Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted chronic lymphocytic leukemia who have received prior ...

    Authors: Stephen K. Tahir, Morey L. Smith, Paul Hessler, Lisa Roberts Rapp, Kenneth B. Idler, Chang H. Park, Joel D. Leverson and Lloyd T. Lam

    Citation: BMC Cancer 2017 17:399

    Content type: Research article

    Published on:

  15. The prognosis of synovial sarcoma (SS), an aggressive soft tissue sarcoma, remains poor. We previously reported that c-MET or platelet-derived growth factor receptor α (PDGFRα) signalling pathway is related to...

    Authors: Shutaro Yamada, Yoshinori Imura, Takaaki Nakai, Sho Nakai, Naohiro Yasuda, Keiko Kaneko, Hidetatsu Outani, Satoshi Takenaka, Kenichiro Hamada, Akira Myoui, Nobuhito Araki, Takafumi Ueda, Kazuyuki Itoh, Hideki Yoshikawa and Norifumi Naka

    Citation: BMC Cancer 2017 17:334

    Content type: Research article

    Published on:

  16. Mesothelioma is resistant to conventional treatments and is often defective in p53 pathways. We then examined anti-tumor effects of metformin, an agent for type 2 diabetes, and combinatory effects of metformin...

    Authors: Kengo Shimazu, Yuji Tada, Takao Morinaga, Masato Shingyoji, Ikuo Sekine, Hideaki Shimada, Kenzo Hiroshima, Takao Namiki, Koichiro Tatsumi and Masatoshi Tagawa

    Citation: BMC Cancer 2017 17:309

    Content type: Research article

    Published on:

  17. Interstitial lung diseases induced by anticancer agents (ILD-AA) are rare adverse effects of anticancer therapy. However, prognostic biomarkers for ILD-AA have not been identified in patients with advanced lun...

    Authors: Kota Nakamura, Motoyasu Kato, Takehito Shukuya, Keita Mori, Yasuhito Sekimoto, Hiroaki Ihara, Ryota Kanemaru, Ryo Ko, Rina Shibayama, Ken Tajima, Ryo Koyama, Naoko Shimada, Osamu Nagashima, Fumiyuki Takahashi, Shinichi Sasaki and Kazuhisa Takahashi

    Citation: BMC Cancer 2017 17:302

    Content type: Research article

    Published on:

  18. Non-small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) gene mutations (exon 19 deletion or exon 21 L858R) respond to EGFR tyrosine kinase inhibitors (EGFR-TKIs). The second...

    Authors: Masato Chiba, Yosuke Togashi, Eri Bannno, Yoshihisa Kobayashi, Yu Nakamura, Hidetoshi Hayashi, Masato Terashima, Marco A. De Velasco, Kazuko Sakai, Yoshihiko Fujita, Tetsuya Mitsudomi and Kazuto Nishio

    Citation: BMC Cancer 2017 17:281

    Content type: Research article

    Published on:

  19. Metastasis is the leading cause of death in breast cancer patients. CD73, also known as ecto-5′-nucleotidase, plays a critical role in cancer development including metastasis. The existing researches indicate ...

    Authors: Xu Yang, Shimin Pei, Huanan Wang, Yipeng Jin, Fang Yu, Bin Zhou, Hong Zhang, Di Zhang and Degui Lin

    Citation: BMC Cancer 2017 17:255

    Content type: Research article

    Published on:

  20. Central nervous system (CNS) brain metastasis of advanced non-small cell lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy comparison of two first-generation epidermal gr...

    Authors: Meng-Xia Li, Hao He, Zhi-Hua Ruan, Yu-Xi Zhu, Rong-Qing Li, Xiao He, Bao-Hua Lan, Zhi-Min Zhang, Guo-Dong Liu, Hua-Liang Xiao, Yan Wu, Bo Zhu, Ge Wang and Zhen-Zhou Yang

    Citation: BMC Cancer 2017 17:245

    Content type: Research article

    Published on:

  21. Expression and activity of heparanase, an endoglycosidase that cleaves heparan sulfate (HS) side chains of proteoglycans, is associated with progression and poor prognosis of many cancers which makes it an att...

    Authors: C. P. Baburajeev, Chakrabhavi Dhananjaya Mohan, Shobith Rangappa, Daniel J. Mason, Julian E. Fuchs, Andreas Bender, Uri Barash, Israel Vlodavsky, Basappa and Kanchugarakoppal S. Rangappa

    Citation: BMC Cancer 2017 17:235

    Content type: Research article

    Published on:

  22. Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to side-effects including hyperglycemia. The AMPK inhibitor and anti-diabetic drug metformin may counteract ev...

    Authors: Gerke Ariaans, Mathilde Jalving, Emma Geertruida Elisabeth de Vries and Steven de Jong

    Citation: BMC Cancer 2017 17:232

    Content type: Research article

    Published on:

  23. Former studies already revealed the anti-neoplastic properties of the anti-infective agent Taurolidine (TRD) against many tumor species in vitro and in vivo. Its anti-proliferative and cell death inducing capacit...

    Authors: M. Buchholz, B. Majchrzak-Stiller, S. Hahn, D. Vangala, R. W. Pfirrmann, W. Uhl, C. Braumann and A. M. Chromik

    Citation: BMC Cancer 2017 17:216

    Content type: Research article

    Published on:

  24. Glioblastoma multiforme (GBM) is the most common, invasive and deadly primary type of malignant brain tumor. The Phosphatidylinositol-3-Kinase/AKT (PI3K/AKT) pathway is highly active in GBM and has been associ...

    Authors: Ravi S. Narayan, Carlos A. Fedrigo, Eelke Brands, Rogier Dik, Lukas J.A. Stalpers, Brigitta G. Baumert, Ben J. Slotman, Bart A. Westerman, Godefridus J. Peters and Peter Sminia

    Citation: BMC Cancer 2017 17:204

    Content type: Research article

    Published on:

  25. Glioblastoma is the most frequent and most malignant brain tumor with the patients having a median survival of only 14.6 months. Although glioblastoma patients are treated with surgery, radiation and chemother...

    Authors: Stine S. Jensen, Stine A. Petterson, Bo Halle, Charlotte Aaberg-Jessen and Bjarne W. Kristensen

    Citation: BMC Cancer 2017 17:178

    Content type: Research article

    Published on:

  26. We previously showed that 1-methylnicotinamide (1-MNA) and its analog 1,4-dimethylpyridine (1,4-DMP) could inhibit the formation of lung metastases and enhance the efficacy of cyclophosphamide-based chemothera...

    Authors: Agnieszka Denslow, Marta Switalska, Marcin Nowak, Magdalena Maciejewska, Stefan Chlopicki, Andrzej Marcinek, Jerzy Gebicki and Joanna Wietrzyk

    Citation: BMC Cancer 2017 17:177

    Content type: Research article

    Published on:

  27. The RAS/RAF/MEK/ERK pathway is constitutively activated in many cancers. Selumetinib (AZD6244, ARRY-142886) is an oral, potent and highly selective, allosteric MEK1/2 inhibitor with a short half-life that has ...

    Authors: Patricia M. LoRusso, Jeffrey R. Infante, Kevin B. Kim, Howard A. Burris III, Gregory Curt, Ugochi Emeribe, Delyth Clemett, Helen K. Tomkinson and Roger B. Cohen

    Citation: BMC Cancer 2017 17:173

    Content type: Research article

    Published on:

  28. Approximately 250 million people worldwide are chronically infected with hepatitis B virus (HBV) and more than half of the hepatocellular carcinoma (HCC) cases are attributed to this infection. As HCC has a hi...

    Authors: Jeffery Fairman, Katherine H. Liu and Stephan Menne

    Citation: BMC Cancer 2017 17:172

    Content type: Research article

    Published on:

  29. Human triple-negative breast cancer has limited therapeutic choices. Breast tumor cells have depolarized plasma membrane potential. Using this unique electrical property, we aim to develop an effective selecti...

    Authors: Han-Gang Yu, Sarah McLaughlin, Mackenzie Newman, Kathleen Brundage, Amanda Ammer, Karen Martin and James Coad

    Citation: BMC Cancer 2017 17:169

    Content type: Research article

    Published on:

  30. Neuroblastoma (NB), a tumor of the primitive neural crest, despite aggressive treatment portends a poor long-term survival for patients with advanced high stage NB. New treatment strategies are required.

    Authors: Reza Bayat Mokhtari, Narges Baluch, Micky Ka Hon Tsui, Sushil Kumar, Tina S. Homayouni, Karen Aitken, Bikul Das, Sylvain Baruchel and Herman Yeger

    Citation: BMC Cancer 2017 17:156

    Content type: Research article

    Published on:

  31. Wogonin is an encouraging choice for clinical use owing to its potent anti-tumor and anti-inflammatory effects with the high safety profile. However, wogonin for targeted therapy of lymphoma was not well addre...

    Authors: Xue Wu, Ping Liu, Haijun Zhang, Yuan Li, Jumah Masoud Mohammad Salmani, Fei Wang, Ke Yang, Rong Fu, Zhewei Chen and Baoan Chen

    Citation: BMC Cancer 2017 17:147

    Content type: Research article

    Published on:

  32. Cisplatin (DDP)-based chemotherapy is the common first-line therapy for lung cancer. However, their efficacy is often limited by primary drug resistance and/or acquired drug resistance. The aim of this study w...

    Authors: Lin Shi, Zhaozhong Xu, Gang Wu, Xiaoting Chen, Yuanyuan Huang, Yanjing Wang, Weiqiang Jiang and Bin Ke

    Citation: BMC Cancer 2017 17:138

    Content type: Research article

    Published on:

  33. The aim of this study was to determine whether checkpoint kinase 1 inihibitor (CHK1), LY2603618, and gemcitabine prolong overall survival (OS) compared to gemcitabine alone in patients with unresectable pancre...

    Authors: Berta Laquente, Jose Lopez-Martin, Donald Richards, Gerald Illerhaus, David Z. Chang, George Kim, Philip Stella, Dirk Richel, Cezary Szcylik, Stefano Cascinu, G. L. Frassineti, Tudor Ciuleanu, Karla Hurt, Scott Hynes, Ji Lin, Aimee Bence Lin…

    Citation: BMC Cancer 2017 17:137

    Content type: Research article

    Published on:

  34. Bacterial toxins have evolved to an effective therapeutic option for cancer therapy. The Clostridium perfringens enterotoxin (CPE) is a pore-forming toxin with selective cytotoxicity. The transmembrane tight junc...

    Authors: Jessica Pahle, Lutz Menzel, Nicole Niesler, Dennis Kobelt, Jutta Aumann, Maria Rivera and Wolfgang Walther

    Citation: BMC Cancer 2017 17:129

    Content type: Research article

    Published on:

  35. Antiangiogenic therapies are considered promising for the treatment of glioblastoma (GB). The non-collagenous C-terminal globular NC1 domain of type VIII collagen a1 chain, Vastatin, is an endogenous antiangio...

    Authors: Yi Li, Jun Li, Yat Ming Woo, Zan Shen, Hong Yao, Yijun Cai, Marie Chia-mi Lin and Wai Sang Poon

    Citation: BMC Cancer 2017 17:126

    Content type: Research article

    Published on:

  36. Photodynamic therapy (PDT) has proven to be a promising alternative to current cancer treatments, especially if combined with conventional approaches. The technique is based on the administration of a non-toxi...

    Authors: Laura Marise de Freitas, Rodolfo Bortolozo Serafim, Juliana Ferreira de Sousa, Thaís Fernanda Moreira, Cláudia Tavares dos Santos, Amanda Martins Baviera, Valeria Valente, Christiane Pienna Soares and Carla Raquel Fontana

    Citation: BMC Cancer 2017 17:123

    Content type: Research article

    Published on:

  37. Glioblastoma Multiforme (GBM) is the most common and lethal form of primary brain tumor in adults. Following standard treatment of surgery, radiation and chemotherapy, patients are expected to survive 12–14 mo...

    Authors: Zachary C. Gersey, Gregor A. Rodriguez, Eric Barbarite, Anthony Sanchez, Winston M. Walters, Kelechi C. Ohaeto, Ricardo J. Komotar and Regina M. Graham

    Citation: BMC Cancer 2017 17:99

    Content type: Research article

    Published on:

  38. Advanced urothelial carcinomas represent a considerable clinical challenge as they are difficult to treat. Platinum-based combination regimens obtain response rates ranging from 40 to 70% in first-line therapy...

    Authors: Sergey A. Dyshlovoy, Ramin Madanchi, Jessica Hauschild, Katharina Otte, Winfried H. Alsdorf, Udo Schumacher, Vladimir I. Kalinin, Alexandra S. Silchenko, Sergey A. Avilov, Friedemann Honecker, Valentin A. Stonik, Carsten Bokemeyer and Gunhild von Amsberg

    Citation: BMC Cancer 2017 17:93

    Content type: Research article

    Published on:

  39. Concurrent cisplatin radiotherapy (CCRT) is a current standard-of-care for locally advanced head and neck squamous cell carcinoma (HNSCC). However, CCRT is frequently ineffective in patients with advanced dise...

    Authors: Martin McLaughlin, Holly E. Barker, Aadil A. Khan, Malin Pedersen, Magnus Dillon, David C. Mansfield, Radhika Patel, Joan N. Kyula, Shreerang A. Bhide, Kate L. Newbold, Christopher M. Nutting and Kevin J. Harrington

    Citation: BMC Cancer 2017 17:86

    Content type: Research article

    Published on:

  40. Osteosarcoma (OS) is the most common primary bone tumor in both humans and dogs and is the second leading cause of cancer related deaths in children and young adults. Limb sparing surgery along with chemothera...

    Authors: Sridhar Murahari, Aimee L. Jalkanen, Samuel K. Kulp, Ching-Shih Chen, Jaime F. Modiano, Cheryl A. London and William C. Kisseberth

    Citation: BMC Cancer 2017 17:67

    Content type: Research article

    Published on:

  41. Norcantharidin (NCTD) is a Chinese FDA approved, chemically synthesized drug for cancer treatment. The effect of NCTD on signaling proteins of EGFR and c-Met was systematically elucidated in current study.

    Authors: Peiju Qiu, Siwen Wang, Ming Liu, He Ma, Xuan Zeng, Meng Zhang, Lingling Xu, Yidi Cui, Huixin Xu, Yang Tang, Yanli He and Lijuan Zhang

    Citation: BMC Cancer 2017 17:55

    Content type: Research article

    Published on:

  42. Despite considerable efforts by scientific research, pancreatic cancer is the fourth leading cause of cancer related mortalities. Sigma-2 receptors, which are overexpressed in several tumors, represent promisi...

    Authors: Maria Laura Pati, John R. Hornick, Mauro Niso, Francesco Berardi, Dirk Spitzer, Carmen Abate and William Hawkins

    Citation: BMC Cancer 2017 17:51

    Content type: Research article

    Published on:

  43. Combination drug therapy appears a promising approach to overcome drug resistance and reduce drug-related toxicities in ovarian cancer treatments. In this in vitro study, we evaluated the antitumor efficacy of...

    Authors: Vijayalakshmi N. Ayyagari, Tsung-han Jeff Hsieh, Paula L. Diaz-Sylvester and Laurent Brard

    Citation: BMC Cancer 2017 17:49

    Content type: Research article

    Published on:

  44. Metabolic toxicities of mTOR inhibitors (mTORi) are well characterized. The purpose of the study was to investigate the relationship between these metabolic toxicities and mTORi efficacy.

    Authors: M. Jebali, R. Elaidi, M. Brizard, J. Fouque, C. Takouchop, B. Sabatier, S. Oudard and J. Medioni

    Citation: BMC Cancer 2017 17:27

    Content type: Research article

    Published on:

  45. In endemic area, nasopharyngeal carcinoma (NPC) tumor cells harbor EBV latent infection and expresses viral antigens such as EBNA1, LMP1 and LMP2. In this study, we established a NPC-mimicry animal model and a...

    Authors: Mei-Chun Lin, Yong-Chong Lin, Syue-Ting Chen, Tai-Horng Young and Pei-Jen Lou

    Citation: BMC Cancer 2017 17:18

    Content type: Research article

    Published on:

  46. Colorectal cancer (CRC) is the 3rd most common type of cancer worldwide. New anti-cancer agents are needed for treating late stage colorectal cancer as most of the deaths occur due to cancer metastasis. A recentl...

    Authors: Khayal Al-Khayal, Ahmed Alafeefy, Mansoor-Ali Vaali-Mohammed, Amer Mahmood, Ahmed Zubaidi, Omar Al-Obeed, Zahid Khan, Maha Abdulla and Rehan Ahmad

    Citation: BMC Cancer 2017 17:4

    Content type: Research article

    Published on:

  47. Colorectal cancer is the second most common cause of cancer deaths for both men and women, and the third most common cause of cancer in the U.S. Toxicity of current chemotherapeutic agents for colorectal cance...

    Authors: Jeffrey Wimsatt, Meghan Villers, Laurel Thomas, Stacey Kamarec, Caitlin Montgomery, Leo W. Y. Yeung, Yanqing Hu and Kim Innes

    Citation: BMC Cancer 2016 16:942

    Content type: Research article

    Published on:

  48. The study was designed to develop a platform to verify whether the extract of herbs combined with chemotherapy drugs play a synergistic role in anti-tumor effects, and to provide experimental evidence and theo...

    Authors: Jun Xie, Jia-Hui Liu, Heng Liu, Xiao-Zhong Liao, Yuling Chen, Mei-Gui Lin, Yue-Yu Gu, Tao-Li Liu, Dong-Mei Wang, Hui Ge and Sui-Lin Mo

    Citation: BMC Cancer 2016 16:899

    Content type: Research article

    Published on:

  49. The polyether antibiotic Salinomycin (Sal) is regarded as an inhibitor of cancer stem cells. Its effectiveness on human colorectal cancer (CRC) cells in vitro has been demonstrated before. The aim of this stud...

    Authors: Johannes Klose, Jana Eissele, Claudia Volz, Steffen Schmitt, Alina Ritter, Shen Ying, Thomas Schmidt, Ulrike Heger, Martin Schneider and Alexis Ulrich

    Citation: BMC Cancer 2016 16:896

    Content type: Research article

    Published on:

  50. Neuroblastoma (NB) is a frequent pediatric tumor characterized by a poor prognosis where a majority of tumors progress despite intensive multimodality treatments. Autophagy, a self-degradative process in cells...

    Authors: Assila Belounis, Carine Nyalendo, Roxane Le Gall, Tina V. Imbriglio, Mohamed Mahma, Pierre Teira, Mona Beaunoyer, Sonia Cournoyer, Elie Haddad, Gilles Vassal and Hervé Sartelet

    Citation: BMC Cancer 2016 16:891

    Content type: Research article

    Published on:

Submit manuscript

Follow

Advertisement

BMC Cancer

ISSN: 1471-2407

Contact us